Recently, Zacks.com users have been paying close attention to Shopify (SHOP). This makes it worthwhile to examine what the stock has in store.
In the most recent trading session, Shopify (SHOP) closed at $156.21, indicating a +2.18% shift from the previous trading day.
SHOP's surging merchant base, AI-driven tools and expanding global reach fuel strong growth, even as the stock trades at a premium.
Shopify is rated a Buy, with a $185 price target, implying 24% upside, due to strong fundamentals and robust e-commerce growth. SHOP delivered double-digit top and bottom line growth in FQ2 2025, consistently beating analyst expectations and outperforming sector peers. Despite trading at a significant premium (forward P/E of 104), SHOP's high margins, rapid growth, and low leverage justify its elevated valuation.
Sabra Health Care REIT is rated a buy with a target price of $19.22, driven by FFO growth and SHOP portfolio expansion. SBRA's shift toward a larger Senior Housing Operating Portfolio aims to capture higher NOI growth, though it introduces more volatility than NNN leases. The REIT offers a 6.6% dividend yield, with improving payout ratios and strong dividend sustainability supported by projected FFO growth.
Shopify (SHOP) closed at $163.87 in the latest trading session, marking a -1.54% move from the prior day.
Since Big Money's first outlier buy in 2019, Shopify, Inc. (SHOP) shares up 698%.
In the most recent trading session, Shopify (SHOP) closed at $151.3, indicating a +1.16% shift from the previous trading day.
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Dave (DAVE) demonstrates superior revenue growth during crucial periods, enhanced profitability, and a relatively lower valuation compared to Shopify (SHOP),indicating that investing in DAVE may be the wiser choice. Separately, see – The GOOGL Stock Shareholder Jackpot.
Shopify's expanding partner base, AI-powered tools and major brand signings highlight the company's strong growth momentum.
A handful of stocks benefited massively during the pandemic. It was an interesting time to be an investor, to say the least, and those who targeted the stay-at-home stocks were rewarded handsomely with considerable gains.